FUS Proteinopathy Neurons

FUS Proteinopathy Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">FUS Proteinopathy Neurons</th>
</tr>
<tr>
<td class="label">Mutation</td>
<td>Protein Change</td>
</tr>
<tr>
<td class="label">R521C</td>
<td>Arginine → Cysteine</td>
</tr>
<tr>
<td class="label">R521G</td>
<td>Arginine → Glycine</td>
</tr>
<tr>
<td class="label">R522G</td>
<td>Arginine → Glycine</td>
</tr>
<tr>
<td class="label">P525L</td>
<td>Proline → Leucine</td>
</tr>
<tr>
<td class="label">P525R</td>
<td>Proline → Arginine</td>
</tr>
<tr>
<td class="label">R487L</td>
<td>Arginine → Leucine</td>
</tr>
<tr>
<td class="label">R487Q</td>
<td>Arginine → Glutamine</td>
</tr>
<tr>
<td class="label">G507D</td>
<td>Glycine → Aspartic Acid</td>
</tr>
<tr>
<td class="label">H517Q</td>
<td>Histidine → Glutamine</td>
</tr>
</table>

Introduction

FUS (Fused in Sarcoma) proteinopathy represents a critical pathological hallmark in a subset of neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). FUS Proteinopathy Neurons are characterized by the accumulation of misfolded FUS protein in the cytoplasm, leading to disruption of normal cellular functions and ultimately neuronal death[@kwiatkowski2009][@vance2009].

This page provides comprehensive information about FUS-positive neurons, their molecular mechanisms, genetic contributors, and therapeutic strategies targeting this pathology.

FUS Proteinopathy Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">FUS Proteinopathy Neurons</th>
</tr>
<tr>
<td class="label">Mutation</td>
<td>Protein Change</td>
</tr>
<tr>
<td class="label">R521C</td>
<td>Arginine → Cysteine</td>
</tr>
<tr>
<td class="label">R521G</td>
<td>Arginine → Glycine</td>
</tr>
<tr>
<td class="label">R522G</td>
<td>Arginine → Glycine</td>
</tr>
<tr>
<td class="label">P525L</td>
<td>Proline → Leucine</td>
</tr>
<tr>
<td class="label">P525R</td>
<td>Proline → Arginine</td>
</tr>
<tr>
<td class="label">R487L</td>
<td>Arginine → Leucine</td>
</tr>
<tr>
<td class="label">R487Q</td>
<td>Arginine → Glutamine</td>
</tr>
<tr>
<td class="label">G507D</td>
<td>Glycine → Aspartic Acid</td>
</tr>
<tr>
<td class="label">H517Q</td>
<td>Histidine → Glutamine</td>
</tr>
</table>

Introduction

FUS (Fused in Sarcoma) proteinopathy represents a critical pathological hallmark in a subset of neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). FUS Proteinopathy Neurons are characterized by the accumulation of misfolded FUS protein in the cytoplasm, leading to disruption of normal cellular functions and ultimately neuronal death[@kwiatkowski2009][@vance2009].

This page provides comprehensive information about FUS-positive neurons, their molecular mechanisms, genetic contributors, and therapeutic strategies targeting this pathology.

Overview

Neurons exhibiting FUS proteinopathy feature cytoplasmic inclusions of mutated or mislocalized FUS protein. FUS mutations are responsible for approximately 5% of familial ALS cases and up to 10% of juvenile-onset ALS[@shang2016]. Unlike TDP-43 proteinopathy, which is the most common pathology in sporadic ALS, FUS pathology is associated with specific genetic subtypes and distinct clinical phenotypes.

The FUS protein is a member of the FET (FUS, EWSR1, TAF15) family of RNA-binding proteins, which are involved in multiple aspects of RNA metabolism including transcription, splicing, transport, and translation[@dormann2011].

FUS Biology

Normal Physiological Function

FUS (Fused in Sarcoma), also known as TLS (Translocated in Sarcoma), is a 526-amino acid nuclear protein with multiple functional domains:

• N-terminal prion-like domain: Enables liquid-liquid phase separation and stress granule formation
• RRM (RNA recognition motif): Binds RNA molecules
• RGG (arginine-glycine-glycine) repeats: Involved in protein-protein interactions
• Zinc finger domain: Mediates nucleic acid binding

• RNA splicing regulation: FUS participates in the spliceosome assembly and regulates alternative splicing of numerous neuronal transcripts
• Transcription regulation: Interacts with RNA polymerase II and transcriptional co-activators
• DNA damage response: FUS is recruited to DNA damage sites and participates in repair pathways
• Stress granule formation: During cellular stress, FUS localizes to stress granules, membrane-less organelles that temporarily store mRNAs
• Axonal transport: Facilitates transport of mRNAs along axons for local protein synthesis

Pathological Changes in FUS Proteinopathy

The transition from normal FUS function to pathological aggregation involves several key steps[@liu2023]:

Genetic Basis

Disease-Causing Mutations

Over 50 FUS mutations have been identified in ALS and FTD patients[@lenz2023]:

Inheritance Patterns

• Autosomal dominant: Most FUS mutations exhibit dominant inheritance
• De novo mutations: Many juvenile cases arise from spontaneous mutations in sperm or egg cells
• Anticipation: Earlier onset in successive generations (controversial)

Affected Brain Regions

FUS proteinopathy preferentially affects specific neuronal populations[@neumann2009]:

Primary Affected Regions

• Motor cortex: Upper motor neurons show FUS inclusions; critical for voluntary movement control
• Spinal cord motor neurons: Lower motor neurons in the anterior horn are severely affected; leads to muscle weakness and atrophy
• Premotor cortex: Involved in movement planning; contributes to pseudobulbar affect
• Primary somatosensory cortex: Some involvement affects sensory processing

Secondary Affected Regions

• Basal ganglia: Particularly the striatum; contributes to movement disorders
• Hippocampus: CA1 and subiculum regions show FUS pathology in some cases
• Frontal cortex: Particularly in FTD cases; affects executive function
• Cerebellar granule cells: Less commonly affected
• Substantia nigra: Dopaminergic neurons may show FUS pathology

Pathogenic Mechanisms

RNA Processing Defects

FUS proteinopathy disrupts multiple aspects of RNA metabolism[@ho2022]:

Alternative Splicing Aberrations

• Intron retention increases in neuronal transcripts
• Exon skipping events disrupt protein coding
• Alternative exon usage alters protein isoforms
• Key neuronal transcripts affected include:
• MAPT (tau)
• UNC13A
• STMN2
• Progranulin (GRN)

• Reduced dendritic mRNA localization
• Impaired local translation at synapses
• Synaptic protein synthesis deficits
• Contributing to synaptic dysfunction

• Global translation reduced due to stress granule sequestration
• Specific translation programs disrupted
• Ribosome stalling on affected transcripts

Stress Granule Dysregulation

Stress granules are membrane-less organelles that form under cellular stress[@dao2021]:

Normal Stress Granule Function

• Form rapidly in response to stress
• Contain translationally stalled mRNAs and RNA-binding proteins
• Resolve when stress subsides
• Protect mRNAs during stress

• Aberrant granule formation even at baseline stress levels
• FUS inclusions persist indefinitely
• Sequestration of essential translational machinery:
• eIF3
• PABPN1
• TDP-43
• Impaired stress response resolution
• Formation of toxic intermediate species

Nucleocytoplasmic Transport Defects

FUS mutations disrupt nuclear-cytoplasmic transport[@japtok2022]:

• Nuclear pore complex integrity compromised
• Importin-α/β trafficking disrupted
• Nuclear envelope breakdown in some cases
• RNA export受阻 (impaired)
• Nuclear accumulation of unspliced transcripts

DNA Damage Sensitivity

FUS plays a direct role in DNA repair[@wang2023]:

Impaired DNA Damage Response

• Reduced recruitment to DNA damage sites
• Defective homologous recombination
• Increased sensitivity to genotoxic stress
• Accumulation of DNA mutations

• Chromosomal breaks increase
• Translocation events more common
• Mutator phenotype develops
• Contributes to neurodegeneration

Mitochondrial Dysfunction

FUS pathology affects mitochondrial health[@tradewell2022]:

• Reduced mitochondrial transport along axons
• Impaired mitochondrial dynamics (fusion/fission)
• Decreased ATP production
• Increased reactive oxygen species (ROS)
• Mitochondrial permeability transition pore opening

Clinical Correlations

ALS Phenotype

• Rapid progression: FUS mutations often cause aggressive disease
• Young onset: Average onset 40-50 years (younger than typical ALS)
• Bulbar onset: More common than in sporadic ALS
• Cognitive involvement: Some develop FTD features
• Respiratory involvement: Early respiratory muscle weakness

FTD Phenotype

• Behavioral variant FTD: Most common presentation
• Language variant: Some develop primary progressive aphasia
• Parkinsonism: May accompany cognitive changes
• Motor neuron disease: Up to 15% develop ALS

Therapeutic Approaches

Antisense Oligonucleotide (ASO) Therapy

ASOs represent the most promising targeted approach[@bhattacharya2024]:

• Mechanism: Single-stranded DNA oligonucleotides that bind complementary mRNA
• FUS-targeted ASOs: Currently in preclinical development
• Delivery: Intrathecal administration to reach CNS
• Challenges:
• Efficient delivery to neurons
• Allele-specific targeting needed for dominant mutations
• Timing of intervention

Small Molecule Approaches

Localization Modulators

• Compounds promoting proper FUS nuclear localization
• Targeting nuclear import machinery
• In development phase

• Inhibiting abnormal stress granule formation
• Promoting granule clearance
• Examples:
• ISRIB (integrated stress response blocker)
• Mitochondrial division inhibitors

• Splicing modifier compounds
• Restoring normal alternative splicing
• Targeting specific mis-spliced events

Gene Therapy

• CRISPR-based approaches: Gene editing to correct mutations
• AAV delivery: Engineered vectors for neuronal transduction
• Allele-specific editing: Targeting mutant allele only
• Regulatory element manipulation: Modulating FUS expression

Neuroprotective Strategies

• Anti-oxidants: Mitigating ROS damage
• Anti-apoptotic compounds: Preventing cell death
• Neurotrophic factors: Supporting neuronal survival
• Mitochondrial stabilizers: Improving energy metabolism

Diagnostic Markers

Biomarkers for FUS Proteinopathy

• CSF FUS levels: Elevated in some patients
• Neurofilament light chain (NfL): Marker of neurodegeneration
• Genetic testing: Confirmatory for mutation carriers
• PET imaging: Experimental tracers for FUS pathology

Research Models

Cellular Models

• Patient-derived iPSCs: Motor neurons from FUS mutation carriers
• Mouse neurons: Primary cultures from transgenic models
• Organoid systems: 3D brain organoids with FUS mutations

Animal Models

• Transgenic mice: Express mutant human FUS
• Knock-in models: Human mutations in endogenous mouse Fus
• C. elegans: Simple model for screening
• Zebrafish: Visual phenotypic screening

See Also

• [Cell Types Indexcell-types)](/cell-types)
• [Brain Regions Indexbrain-regions)
• ALS Disease Page
• FTD Disease Page
• [TDP-43 Proteinopathy](/proteins/tdp-43)
• [Stress Granules](/mechanisms/stress-granules)
• [RNA Metabolism](/mechanisms/rna-metabolism)